Show simple item record

dc.contributor.authorAl-Kaisi, Firas
dc.date.accessioned2023-04-04T13:26:19Z
dc.date.available2023-04-04T13:26:19Z
dc.date.issued2023-04
dc.identifier.citationBr J Haematol. 2023 Apr;201(1):162-167. doi: 10.1111/bjh.18672. Epub 2023 Jan 31.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/16707
dc.subjectFrailtyen_US
dc.subjectisatuximaben_US
dc.subjectMyelomaen_US
dc.subjectPomalidomideen_US
dc.subjectReal-Worlden_US
dc.titleFrailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.en_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecord10.1111/bjh.18672en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record